The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksQFI.L Regulatory News (QFI)

  • There is currently no data for QFI

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Wärtsilä Testing Update

3 Mar 2023 07:00

RNS Number : 7432R
Quadrise Fuels International PLC
03 March 2023
 

3 March 2023

Quadrise Fuels International Plc ("Quadrise" or the "Company")

Wärtsilä Testing Update

Quadrise Fuels International Plc (AIM:QFI), the supplier of innovative energy solutions for a cleaner planet, provides the following update further to the Company's announcement of 16 January 2023, on the testing of its bioMSAR™ fuel carried out by Wärtsilä Services Switzerland ("Wärtsilä") in December 2022.

As part of Quadrise's ongoing Framework Agreement with MSC Shipmanagement, optical combustion and engine wear tests of bioMSAR™ were carried out as a necessary precursor to commercial-scale vessel trials.

The optical combustion test, against MSAR® and diesel fuels, has confirmed bioMSAR™ to have similar injection and combustion properties as MSAR® and that bioMSAR™ is therefore expected to behave similarly to MSAR® when utilised in medium and slow-speed diesel engines.

Extended wear tests over a 250 hour period were also completed successfully. 

The Company is pleased to confirm that, as a result of these test results, bioMSAR™ can proceed to the next phase of assessment, with hazard identification and operability studies now scheduled ahead of commercial vessel testing on the MSC Leandra and further announcements will be made, as appropriate, in due course.

Jason Miles, Chief Executive of Quadrise, commented:

 

"The extensive tests undertaken by Wärtsilä clearly demonstrate the suitability of bioMSAR™ for use in both marine and power plant applications. This is an important step in clearing the fuel for commercial supply and we look forward to progressing our final round of tests ahead of planned vessel trials with MSC for both MSAR® and bioMSAR™ later this year."

 

For additional information, please contact:

 

Quadrise Fuels International Plc

+44 (0)20 7031 7321

Andy Morrison, Chairman

Jason Miles, Chief Executive Officer

Nominated Adviser

Cenkos Securities plc

+44 (0)20 7397 8900

Ben Jeynes

Katy Birkin

Broker

Shore Capital Stockbrokers Limited

 

 

+44 (0)20 7408 4090

Toby Gibbs, Rachel Goldstein (Corporate Advisory)

Fiona Conroy (Corporate Broking)

Public & Investor Relations

 

 

Vigo Consulting

Patrick D'Ancona

Charlie Neish

+44 (0)20 7390 0230

 

About Quadrise

Quadrise is the supplier of MSAR® and bioMSAR™ emulsion technology, fuels and biofuels, providing innovative solutions to reduce energy costs and greenhouse gas emissions today for clients in the global power generation, shipping, industrial and refining industries.

Learn more: www.quadrisefuels.com

 

Certain of the information contained within this announcement is deemed by the Company to constitute inside information as stipulated under The Market Abuse Regulation (EU 596/2014) pursuant to the Market Abuse (Amendment) (EU Exit) Regulations 2018. Upon the publication of this announcement via a Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDSSIEFEEDSESD
Date   Source Headline
2nd Feb 20217:00 amRNSUpdate re Morocco and Greenfield Energy Projects
1st Feb 20217:00 amRNSUpdate re bioMSAR Testing at Aquafuel Research Ltd
27th Jan 20217:00 amRNSIssue of Equity
21st Jan 20217:00 amRNSJoint Development Agreement - MSC Shipmanagement
6th Jan 20217:00 amRNSIssue of Equity
4th Jan 20217:00 amRNSChange of Registered Office
18th Dec 202011:46 amRNSUpdate re Greenfield MSAR Trial
18th Dec 20207:00 amRNSbioMSAR Testing Update & Collaboration Agreement
15th Dec 20207:00 amRNSLaunch of bioMSAR
3rd Dec 20207:00 amRNSPublication of Americas White Paper
27th Nov 202012:13 pmRNSResult of AGM
27th Nov 20207:00 amRNSAGM Statement
24th Nov 20208:00 amEQSQuadrise Fuels International (QFI): The clean solution to a global problem
2nd Nov 20205:23 pmRNSPosting of Annual Report and Notice of AGM
26th Oct 20207:00 amRNSMorocco Update
5th Oct 20207:00 amRNSFinal Results, Investor Presentation & AGM Notice
7th Sep 20205:56 pmRNSIssue of Equity
7th Sep 20207:00 amRNSNotice of Results, Update and Investor Event
24th Aug 20207:00 amRNSIssue of Share Options
20th Aug 20207:00 amRNSIssue of Equity
18th Aug 20207:22 amRNSGreenfield MSAR Commercial Trial Agreement
17th Aug 20207:00 amRNSPublication of White Paper
17th Jul 20203:59 pmRNSInvestor Presentation
30th Jun 20209:18 amRNSHolding(s) in Company
24th Jun 20204:41 pmRNSSecond Price Monitoring Extn
24th Jun 20204:37 pmRNSPrice Monitoring Extension
23rd Jun 20207:00 amRNSIssue of Equity
18th Jun 20207:00 amRNSStatement re MSAR Licensing and Upstream Trial
17th Jun 20201:47 pmRNSStatement re MSAR Licensing
2nd Jun 20207:00 amRNSInvestor Presentation
1st May 20207:00 amRNSFurther Statement re Covid-19 and Update
16th Apr 20202:21 pmRNSIssue of Equity
15th Apr 20207:00 amRNSDirectorate Change
30th Mar 20204:13 pmRNSNew Website
30th Mar 202011:02 amRNSHalf-year Report - Replacement
30th Mar 20207:00 amRNSHalf-year Report
24th Mar 202010:13 amRNSIssue of Equity
16th Mar 20207:00 amRNSStatement re Covid-19 and Morocco Pilot Trial
5th Mar 20209:10 amRNSUpdate on Morocco Pilot Trial
17th Feb 20207:00 amRNSNotice of Interim Results and Business Update
30th Jan 20207:00 amRNSAppointment of New Auditors
15th Jan 20207:00 amRNSDirectorate Changes
16th Dec 20198:38 amRNSDirectorate Change
29th Nov 20194:42 pmRNSResult of AGM
29th Nov 20197:05 amRNSIssue of Warrants
29th Nov 20197:00 amRNSAGM Update
29th Nov 20197:00 amRNSMaterial Transfer & Cooperation Agreement
6th Nov 20195:03 pmRNSPosting of Annual Report and Notice of AGM
10th Oct 20195:42 pmRNSHolding(s) in Company
8th Oct 20197:00 amRNSNew three-year Exclusive Agreement with Nouryon

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.